Literature DB >> 7889306

Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity.

N M Rupniak1, S Patel, R Marwood, J Webb, J R Traynor, J Elliott, S B Freedman, S R Fletcher, R G Hill.   

Abstract

1. Epibatidine is an analgesic substance, isolated from the skin of the poisonous frog Epipedobates tricolor, for which the mechanism of action was previously unknown. 2. The IC50 of synthetic (+)-epibatidine oxalate (the naturally occurring isomer) for [3H]-nicotine binding to rat whole-brain membranes was 0.1 nM. The (-)-isomer also exhibited high affinity (IC50 = 0.2 nM). 3. (+)- and (-)-Epibatidine exhibited much lower affinity for displacement of the muscarinic ligand [3H]-N-methylscopolamine binding to rat cortical membranes (Kapp = 6.9 microM and 16.0 microM respectively). The (+)-enantiomer of epibatidine had an antagonist/agonist (NMS/oxo-M) binding ratio of 4.2 This is consistent with a muscarinic antagonist profile. 4. (+)-Epibatidine oxalate (10 microM) did not cause significant (> 30%) displacement of radioligand binding to opioid, excitatory amino acid, benzodiazepine, 5-HT, dopamine, adrenaline or peptide receptors. 5. (+)- and (-)-Epibatidine (5-20 micrograms kg-1 s.c.) doubled response latency in the mouse hot-plate test. Antinociception and behavioural depression induced by (+)-epibatidine (5 micrograms kg-1) was fully blocked by the nicotinic antagonists mecamylamine (2 mg kg-1 s.c.) or dihydro-beta-erythroidine (2 mg kg-1 s.c.). The muscarinic antagonist scopolamine (0.4 and 10 mg kg-1 s.c.) caused partial reversal of antinociception induced by (+)-epibatidine in mice, but not in rats. 6. These findings demonstrate that (+)-epibatidine oxalate salt is a highly selective and potent nicotinic analgesic agent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889306      PMCID: PMC1510487          DOI: 10.1111/j.1476-5381.1994.tb17164.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Antinociceptive effects of Ca2+ channel blockers.

Authors:  H F Miranda; D Bustamante; V Kramer; T Pelissier; H Saavedra; C Paeile; E Fernandez; G Pinardi
Journal:  Eur J Pharmacol       Date:  1992-07-07       Impact factor: 4.432

2.  Hypoalgesia induced by the local injection of carbachol into the nucleus raphe magnus.

Authors:  M S Brodie; H K Proudfit
Journal:  Brain Res       Date:  1984-01-23       Impact factor: 3.252

3.  Classification of skin alkaloids from neotropical poison-dart frogs (Dendrobatidae).

Authors:  J W Daly; G B Brown; M Mensah-Dwumah; C W Myers
Journal:  Toxicon       Date:  1978       Impact factor: 3.033

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Epibatidine, a potent analgetic and nicotinic agonist.

Authors:  B Badio; J W Daly
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

6.  Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels.

Authors:  H L Tripathi; B R Martin; M D Aceto
Journal:  J Pharmacol Exp Ther       Date:  1982-04       Impact factor: 4.030

7.  Involvement of calcium and L-type channels in nicotine-induced antinociception.

Authors:  M I Damaj; S P Welch; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

Review 8.  Beneficial effects of nicotine.

Authors:  M E Jarvik
Journal:  Br J Addict       Date:  1991-05

Review 9.  The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo.

Authors:  S B Freedman; G R Dawson; L L Iversen; R Baker; R J Hargreaves
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

10.  Epibatidine is a nicotinic analgesic.

Authors:  C Qian; T Li; T Y Shen; L Libertine-Garahan; J Eckman; T Biftu; S Ip
Journal:  Eur J Pharmacol       Date:  1993-12-21       Impact factor: 4.432

View more
  5 in total

Review 1.  Pain, nicotine, and smoking: research findings and mechanistic considerations.

Authors:  Joseph W Ditre; Thomas H Brandon; Emily L Zale; Mary M Meagher
Journal:  Psychol Bull       Date:  2011-11       Impact factor: 17.737

2.  Interaction between midazolam and epibatidine in spinally mediated antinociception in rats.

Authors:  Tomoki Nishiyama
Journal:  J Anesth       Date:  2009-08-14       Impact factor: 2.078

Review 3.  Epibatidine: impact on nicotinic receptor research.

Authors:  Małgorzata Dukat; Richard A Glennon
Journal:  Cell Mol Neurobiol       Date:  2003-06       Impact factor: 5.046

Review 4.  Neuronal nicotinic receptors as analgesic targets: it's a winding road.

Authors:  Iboro C Umana; Claire A Daniele; Daniel S McGehee
Journal:  Biochem Pharmacol       Date:  2013-08-12       Impact factor: 5.858

Review 5.  Pyridine alkaloids with activity in the central nervous system.

Authors:  Simon X Lin; Maurice A Curtis; Jonathan Sperry
Journal:  Bioorg Med Chem       Date:  2020-10-16       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.